Fable
5 known investors
Find your way into Fable
Fable Therapeutics is a biotech company using protein engineering to develop biologics targeting the activin receptor type II (ActR2) pathway for obesity and related metabolic diseases. Its pipeline addresses body composition and broader metabolic health rather than weight loss alone, serving patients with obesity and cardiometabolic comorbidities.
Founders & leadership
GM
Geoff MacKayPresident & CEO
DB
David BakerChief Scientific Officer
RW
Rhonda WidemanChief Business Officer
ZM
Zack McNealyChief Financial Officer
Investors · 5
Competitors · 2
by search overlapApplied Therapeutics11 shared keywordsApplied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need. Its Aldose Reductase Inhibitor franchise is in development across disease areas including Galactosemia and SORD Deficiency.
Mission BioCapital Platinum Program Holdings LLC10 shared keywordsMission BioCapital is a venture capital firm that invests in early-stage life science companies, from therapeutics and drug discovery to biotech tools and diagnostics. The firm provides capital, operational support, and lab infrastructure through its MBC BioLabs co-working spaces to help scientific entrepreneurs launch and scale biotech startups.
Companies competing with Fable for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Fable do?
- Fable Therapeutics is a biotech company using protein engineering to develop biologics targeting the activin receptor type II (ActR2) pathway for obesity and related metabolic diseases. Its pipeline addresses body composition and broader metabolic health rather than weight loss alone, serving patients with obesity and cardiometabolic comorbidities.
- Who are Fable's investors?
- Fable's investors include MPM BioImpact, DCVC Bio, Lilly Asia Ventures, Versant Ventures, DCVC (Data Collective).